ResMed expands board of directors
By HME News Staff
Updated 8:31 AM CDT, Mon August 19, 2024
SAN DIEGO – ResMed has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board. DelOrefice, who currently serves as executive vice president and CFO of Becton, Dickinson and Company, was appointed during ResMed’s regularly scheduled board meeting on Aug. 15 and will stand for re-election with the rest of the company’s directors at its annual meeting on Nov. 21. “Chris has proven himself an experienced global leader in corporate finance and business strategy, as well as in global operations management across multiple business sectors, including in his current role as CFO of a multi-billion dollar, global med-tech company,” said Mick Farrell, chairman and CEO of ResMed. “My fellow board members and I were impressed with Chris’ achievements, as well as his humility, hard-working nature, and leadership capabilities, all of which are highly relevant to his service as a ResMed director. Chris’ financial experience in health care and medical technology will complement the leaders already serving as ResMed directors.” ResMed has also appointed DelOrefice to the board’s audit committee. He has more than 30 years of audit, finance and strategic expertise that includes roles at Johnson & Johnson, AstraZeneca, AET Films and Ametek.
Comments